How many investments has Novartis Venture Fund made?

Novartis Venture Fund has 30 tracked investments, including 4 dated in the last 24 months.

What stage does Novartis Venture Fund invest at?

Novartis Venture Fund invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.

What is Novartis Venture Fund's typical check size?

Novartis Venture Fund typically writes checks of $5M – $25M.

What sectors does Novartis Venture Fund focus on?

Novartis Venture Fund focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is Novartis Venture Fund located?

Novartis Venture Fund is headquartered in Basel, CH.

Does Novartis Venture Fund lead rounds?

Yes, Novartis Venture Fund leads investment rounds.

Who does Novartis Venture Fund co-invest with?

Novartis Venture Fund most often shares deals with Pfizer Venture Investments, OrbiMed, SV Health Investors, among 63 tracked co-investors.

Novartis Venture Fund

Corporate VC

Basel · Pre-Seed–Late Stage · 23 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

The Novartis Venture Fund backs innovative life science companies working in biotechnology and biopharmaceuticals across a range of stages, from early-stage startups to later-stage companies. It seeks to develop novel therapeutics and platforms that address unmet patient needs across the healthcare spectrum. The fund takes a hands-on approach, working closely with boards and management to deliver clinical impact. Its team, split between Basel and Cambridge, has expertise in drug development across diverse therapeutic areas and modalities. The fund manages over USD 750 million in committed capital and holds more than 40 portfolio companies across North America and Europe.

Invests inBiotech Digital Health Healthtech Medical Devices Europe North America Switzerland United States

Source: firm website, verified Aug 3, 2026.

Stage

Pre-Seed–Late Stage

Check

$5M – $25M

Basel, MA, CH

Leads rounds

Leads

Instruments

Equity

Founded

1996

Last 12 months

2 investments

AUM

$750M

Tracked investments

Team · 23 people

from the firm's website & public directories

Anja Koenig· Global Head of NVF· Basel, CHin

Bart Dzikowski· Managing Director· Basel, Switzerlandin

Bart Dzikowski is a Managing Director at the Novartis Venture Fund, where he heads Transactions & Legal. Before this role he held senior positions in Novartis' Transactions groups, which he joined in 2009, and earlier worked as a VP in investment banking at Bank of America/Merrill Lynch and as a transactions attorney at Allen & Overy in New York. He holds Juris Doctor and Civil Law degrees from McGill Law School and is a member of the New York State Bar.

b•••@novartis.comreveal

Florian Muellershausen· Managing Director· Basel, Switzerlandin

Florian Muellershausen, PhD, is a Managing Director at the Novartis Venture Fund based in Basel, Switzerland. Before joining the fund, he served as a Scientific Manager for the R&D Committee of the Novartis Board of Directors and held drug discovery roles in Novartis R&D, including Laboratory Head in target discovery and Translational Medicine Expert in autoimmunity. He holds an MSc in Biochemistry from Free University Berlin, a PhD in Biochemistry from Ruhr University Bochum, and completed postdoctoral training at Novartis in Switzerland.

Laura Brass· Managing Director· Cambridge, MA, USAin

Laura Brass is a Managing Director at the Novartis Venture Fund. She previously served as a Managing Director at MPM Capital and was part of the founding management team and SVP of Business Development at TriNetX, and earlier was CEO of the early-stage antiviral company Aferon. She holds a BA in Philosophy and BS in Biochemistry from the University of Missouri-Columbia, and a PhD in Molecular Genetics and Cell Biology and an MBA from the University of Chicago.

l•••@novartis.comreveal

Marianne Uteng· Managing Director· Basel, Switzerlandin

Marianne Uteng, PhD, is a Managing Director at Novartis Venture Fund in Basel. She previously worked in Novartis Global Drug Development and its Pre-Clinical Safety Department, leading teams on safety assessments for early and late-stage programs, and supported Novartis BD&L Search & Evaluation while building collaborations with biotech companies and academia. She holds an MSc in Biochemistry from the University of Oslo and a PhD in Molecular Biology, Cell Biology & Biophysics from a joint EMBL–University of Oslo program.

m•••@novartis.comreveal

Aaron Nelson· Managing Director· Cambridge, Massachusettsin

Aaron Nelson is a Partner at Novo Holdings with a background spanning academic research, pharmaceutical development, and digital medicine. His current focus is therapeutic chemical and biological technologies.

a•••@novartis.comreveal

Florian Müellershausen· Managing Director· Basel, Switzerland

Florian Muellershausen, PhD, is a Managing Director at the Novartis Venture Fund. Before joining NVF, he served as a Scientific Manager for the R&D Committee of the Novartis Board of Directors and previously held drug discovery roles in Novartis R&D, including Laboratory Head in target discovery and Translational Medicine Expert in autoimmunity within early clinical research. He holds an MSc in Biochemistry from Free University Berlin, a PhD in Biochemistry from Ruhr University Bochum, and completed postdoctoral training at Novartis in Switzerland.

f•••@novartis.comreveal

Michal Silverberg· Managing Director· Boston, Massachusettsin

m•••@novartis.comreveal

Henry Skinner· Managing Director· Massachusettsin

Adam Cotton· Principal· Cambridge, MA, USAin

Adam Cotton is a Principal at the Novartis Venture Fund. Before joining the firm, he conducted antibody engineering research in the labs of Jim Wells and Ian Seiple, and he is a scientific co-founder of Epi Biologics who also contributed to establishing Rezo Therapeutics and HYKU Biosciences as they emerged from academic labs. He holds a BA in Chemistry from Harvard University, an MBA from the University of New Mexico, and a PhD in Chemistry & Chemical Biology from the University of California, San Francisco.

Beat Steffen· Principal· Basel, Switzerlandin 𝕏

Beat Steffen is a Managing Director at the Novartis Venture Fund. He previously held commercial roles at Novartis Pharmaceuticals in the US and Switzerland, launching products in the cardiovascular area, and earlier worked at McKinsey & Company in Zurich with pharmaceutical clients. He is a Swiss-trained physician specializing in cardiovascular surgery and intensive care and holds an MBA from INSEAD.

b•••@novartis.comreveal

Mathias Frederiksen· Principal· Basel, Switzerlandin

Mathias Frederiksen is a Principal at the Novartis Venture Fund, based in Basel. Before joining NVF, he was a group leader in Novartis R&D, where his work covered neuroscience-focused medicinal chemistry, chemical genomics, and target discovery, with a focus on epigenetic dysregulation in disease, and he served on the portfolio management and strategy team. He holds a BSc in Chemistry from Mount Allison University, a PhD in Chemistry from Imperial College London, and completed a postdoctorate at Stanford University.

Christoph Meier· Prof. Christoph A. Meier, MD· Zurich, Switzerland

Christoph A. Meier, MD, is Head of the Department of Internal Medicine at the University Hospital Zurich and Professor at the Medical Faculty of the University of Geneva. He previously served as Chief Medical Officer and deputy CEO at the University Hospital Basel, and held leadership roles in internal medicine and endocrinology at Triemli Hospital in Zurich and the University Hospital Geneva. He earned his medical degree from the University of Basel and completed fellowships at the NIH, Brigham and Women's Hospital, and Massachusetts General Hospital/Harvard Medical School.

Elaine Jones· Dr.

Elaine Jones holds a PhD and has over 20 years of experience as a life science-focused venture capitalist. She was previously Vice President of Venture Capital at Pfizer Ventures, a General Partner at EuclidSR Partners, and began her investing career at S.R. One, the corporate fund of GlaxoSmithKline; earlier she was Director of Scientific Licensing and a research scientist at SmithKline Beecham. She earned a BS in Biology from Juniata College and a PhD in Microbiology from the University of Pittsburgh, with postdoctoral research at the National Institutes of Health.

Elena Battistello· Analyst· Zurich, Switzerlandin 𝕏

Elena Battistello is an Analyst at the Novartis Venture Fund. Before joining the firm, she was a postdoctoral fellow at the New York University School of Medicine working on cancer immunotherapies, and prior to that she conducted research on targeted therapy and immunotherapy for blood tumors at EPFL. She holds a BSc from Padua University, a double MSc from Paris-Diderot University and Padua University, and a PhD from EPFL.

Fiona H. Marshall· President of Biomedical Research, Novartisin

Fiona H. Marshall holds a PhD and serves as President of Biomedical Research at Novartis and sits on the company's Executive Committee, having joined in 2022. She previously led Discovery Sciences, Preclinical Development and Translational Medicine at MSD (Merck & Co.), and before that co-founded Heptares Therapeutics, where she was Chief Scientific Officer through its acquisition by Sosei. Earlier roles included Director of Molecular Pharmacology at Millennium Pharmaceuticals and senior positions at GSK; she earned a BSc in Biochemistry from the University of Bath and a PhD in Neuroscience from the University of Cambridge.

Michael Gilman· Dr.

Michael Gilman, PhD, is a scientist, general manager, biotech executive and entrepreneur. He founded and led Padlock Therapeutics (acquired by Bristol-Myers Squibb in 2016) and Stromedix (acquired by Biogen Idec), and held senior research and pipeline roles at Biogen Idec and ARIAD Pharmaceuticals. Earlier he was on the scientific staff at Cold Spring Harbor Laboratory; he holds a PhD in Biochemistry from UC Berkeley and an SB in Life Science from MIT.

Michael Hengartner· President of the ETH Board and Chairman of the Executive Committee of the ETH Domain

Michael Hengartner, PhD, MBA, is President of the ETH Board and Chairman of the Executive Committee of the ETH Domain. He previously served as Rector of the University of Zurich (2014-2020) and President of swissuniversities (2016-2020). He studied biochemistry at the Université Laval, earned his PhD at MIT in 1994, led a research group at Cold Spring Harbor Laboratory, and later held a professorship at the University of Zurich, focusing his research on the molecular basis of apoptosis.

Michelle Ma· Analyst· Boston, Massachusettsin

Michelle Ma is an Associate at the Novartis Venture Fund based in Cambridge, MA. Before joining the firm, she conducted research in Eric Fischer's lab, where her thesis examined mechanisms of protein degraders using biochemistry and structural biology. She earned a BA in Molecular and Cell Biology from UC Berkeley and a PhD in Biochemistry from Harvard University.

Mukul Mehta· Chief Financial Officer of Novartis

Mukul Mehta was appointed Chief Financial Officer of Novartis in March 2026, following more than 20 years in finance roles across the company's Commercial, Development, Business Services, and Corporate Finance functions since 2003. Before that role he oversaw Business Planning & Analysis, Digital Finance, and Tax, and earlier worked in India's heavy engineering and banking sectors. He holds an MBA from INSEAD and a bachelor's degree in Electrical Engineering from PEC Chandigarh, India.

Samantha Guinn· Analyst· Cambridge, MA, USAin

Samantha Guinn, PhD, is an Analyst at the Novartis Venture Fund. She was previously an Associate at Flagship Pioneering, where she worked on venture hypotheses, therapeutic concepts, and landscaping assessments, and earlier conducted research in the lab of Dr. Elizabeth Jaffee focused on cancer-associated fibroblast cellular crosstalk in pancreatic cancer. She holds a BSc from Colorado State University, an MMSc in Immunology from Harvard Medical School, and a PhD in Immunology from Johns Hopkins University School of Medicine.

Shreeram Aradhye· President, Development and Chief Medical Officer, Novartis; Member of the Novartis Executive Committeein

Shreeram Aradhye, MD, is President of Development and Chief Medical Officer at Novartis and a member of its Executive Committee, overseeing advancement of the company's pipeline of investigational medicines. He first joined Novartis in 1999 and held leadership roles across the US, Switzerland, Germany, and India before spending several years at US biotechnology companies, including leading development of clinical-stage RNAi assets at Dicerna Pharmaceuticals, then rejoined Novartis in May 2022. Earlier he was a transplant nephrologist, attending physician, and assistant professor of medicine at the University of Pennsylvania, and completed his medical training at the All India Institute of Medical Sciences in 1989.

Anja König· Global Head of the Novartis Venture Fund· Basel, Switzerlandin

Anja Koenig, who holds a PhD in Physics from Cornell University, leads the Novartis Venture Fund and was previously a Managing Director at the fund covering Switzerland, the UK, the rest of Europe, and Asia/Pacific. Before joining NVF, she was an Associate Partner at McKinsey and Company in New York, working with healthcare companies across the US, Europe, and emerging markets. She is involved in the Swiss startup ecosystem and serves on the board of Sensirion, a publicly listed Swiss engineering company.

a•••@novartis.comreveal

Founder mafia

2 people who came through Novartis Venture Fund went on to found or lead other companies.

Adam CottonPrincipalFounded Epi Biologics Huw NashConsultantFounded Aileron Therapeutics

What they invest in

from 40 of 48 portfolio companies

Biotech ×37Healthtech ×21Medical Devices ×15Deep Tech ×9Digital Health ×4AI & Machine Learning ×2Cybersecurity ×1Enterprise Software ×1

HQs:United States×15Switzerland×4United Kingdom×2Netherlands×2Australia×1Colombia×1

Who they back

founder profiles across 8 portfolio companies

38%

solo founders

3 of 8 mapped founding teams

Founding team size:solo founder×32 founders×44+ founders×1

Investments · 48 tracked

founders shown can be your intro path

By year:2025 · 4 2024 · 1 2023 · 1 2022 · 1 2021 · 1 2020 · 1 2012 · 110 dated

Adicet Bioadicetbio.comNASDAQ: ACET

Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer.

BiotechHealthtechMenlo Park, US

Aya Jakobovits(Executive Officer, Director)Nathan Hubbard(Executive Officer)

BoardJonathan Silverstein(Director)inCarl Gordon(Director)inFlorent Gros(Director)Erez Chimovits(Director)in

Co-investorsForesite Capital OrbiMed Pontifax Venture Capital Quan Capital aMoon

Aileron Therapeutics inNASDAQ: RNTX

BiotechCambridge, US

Manuel Aivado(Executive Officer)Enrico Petrillo(Director)

BoardCaleb Winder(Director)inSeth L. Harrison(Director)Reinhard J. Ambros(Director)Joseph A. Yanchik III(Executive Officer, Director)in

Co-investorsExcel Venture Management

Aravaxaravax.com.au inJan 2024 · $66M✓ verified

Aravax is a clinical-stage biotechnology company developing next-generation immunotherapies to treat food allergies.

BiotechHealthtechMedical DevicesMelbourne, AU

Sara Prickett(Co-founder)

Co-investorsTenmile Breakthrough Victoria UniSeed Pty Ltd.

GentiBiogentibio.com in 𝕏✓ verified

GentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases.

BiotechHealthtechMedical Devices

Jane Buckner(Scientific Co-founder (President, Benaroya Research Institute))Chandra Patel(Co-founder & SVP, Research and Development Operations)David Rawlings(Scientific Co-founder and Senior Scientific Advisor)Andy Scharenberg(Scientific Co-founder, SAB Chair)Andy Walker(President and CEO)Tom Wickham(Chief Scientific Officer)

Co-investorsOrbiMed JDRF T1D Fund RA Capital

Granite Biogranitebio.com inApr 2025 · $100M✓ verified

Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options.

BiotechMedical DevicesBasel, CH

Patrick Loustau(President and Chief Executive Officer)

Co-investorsSanofi Ventures Forbion Versant Ventures

HYKU Bioscienceshykubiosciences.com inDec 2025✓ verified

Hyku Biosciences develops small molecule therapeutics with novel mechanisms of action designed to covalently bind non-cysteine amino acids and inactivate disease-driving proteins.

BiotechDeep TechMedical DevicesBurlington, US

KLEEM CHAUDHARY(Executive Officer, Director, Promoter)Ku-Lung (Ken) Hsu, PhD(Endowed Associate Professor of Chemistry)Kleem Chaudhary, PhD(President & CEO)

BoardJOHN GUSTOFSON(Director)LAURA BRASS(Director)inLAURA TADVALKAR(Director)

Co-investorsDroia Ventures Eisai Innovation, Inc.RA Capital

ONL Therapeuticsonltherapeutics.com in✓ verified

ONL Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve sight by preventing Fas-mediated death of retinal cells, a cause of vision loss and blindness.

BiotechHealthtechMedical DevicesAnn Arbor, US

David Zacks(Co-Founder & Chief Scientific Officer)David Esposito(Executive Officer, Director)Constance Chang(Executive Officer)John K Freshley(Executive Officer, Director)Jeffrey A Jamison(Executive Officer)David N Zacks(Executive Officer, Director)

Co-investorsExSight Ventures Invest Michigan Visionary Ventures Bios Partners InFocus Capital Partners, LLC Johnson & Johnson Innovation – JJDC +3 more

RhyGaze AGrhygaze.com in✓ verified

RhyGaze develops gene therapies using optogenetic proteins to restore sight in patients with vision loss caused by retinal photoreceptor dysfunction.

BiotechDigital HealthMedical DevicesBasel, CH

Botond Roska(Researcher (M.D., Ph.D.))Bence György(IOB Assistant Professor & Head of Clinical Translation)Katherine High(CEO)

Co-investorsARCH Venture Partners BioGeneration Ventures F-Prime Capital GV (Google Ventures)

Splice Biosplice.bio in 𝕏✓ verified

SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes.

BiotechDeep TechDigital HealthBarcelona, ES

Dr. Vila-Perelló(CEO)Dr. Frutos(Co-founder)

Co-investorsRoche Venture Fund Sanofi Ventures Ysios Capital Asabys Partners Criteria Bio Ventures New Enterprise Associates (NEA)+2 more

Vivet Therapeuticsvivet-therapeutics.com in 𝕏✓ verified

Vivet Therapeutics is a clinical-stage biotechnology company developing recombinant adeno-associated virus (rAAV) gene therapies for rare, inherited metabolic diseases, including Wilson's Disease and cerebrotendinous xanthomatosis.

BiotechHealthtechParis, FR

Co-investorsHealthCap Kurma Partners Roche Venture Fund Ysios Capital Columbus Venture Partners Eurazeo +1 more

ImmPACT Bio USA Inc.Jul 2020SEC filingmedium confidence

West Hills, US

Board seatMichal Silverberg· per SEC Form D · $5.5M raise · filed Aug 2020

Co-investorsDecheng Capital RMGP Biopharma Investment Fund venBio Global Strategic

Mediar Therapeuticsmediartx.com inNov 2022

Mediartx develops novel therapies for patients with fibrotic diseases.

BiotechMedical DevicesBoston, US

Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)inRahul Ballal(Executive Officer, Director)Brian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)

Board seatAnja Koenig· per SEC Form D

Co-investorsLongwood Fund Mission Biocapital Ono Venture Investment, Inc.Pfizer Venture Investments ShangBay Capital LLC Sofinnova Partners +2 more

0 2 AstronauTxastronautx.bio in

Co-investorsMPM BioImpact SV Health Investors UCL Technology Fund

Alestaalestatherapeutics.com in

Alesta Therapeutics is a biotech company developing oral small molecule therapies for rare diseases with limited treatment options.

BiotechHealthtech

Co-investorsDroia Ventures Frazier Life Sciences Frazier Healthcare Partners RTW Investments L.P.Thuja Capital

Amphistaamphista.com in 𝕏

Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins.

BiotechCambridge, GB

Louise Modis(Chief Executive Officer)Martin Pass(Chief Development Officer)Giles Brown(Executive VP Drug Discovery)

Co-investorsAdvent Life Sciences SV Health Investors Dementia Discovery Fund European Investment Fund Forbion Gilde Healthcare +1 more

Anaveonanaveon.com in

Anaveon develops engineered antibodies targeting immune system regulatory nodes to treat autoimmune diseases by selectively eliminating or reprogramming pathogenic immune cells.

BiotechBasel, CH

Thaminda(Chief Business Officer)inLaetitia Pouzol(Chief Scientific Officer)in

Co-investorsPfizer Venture Investments Pontifax Venture Capital

Artios

Co-investorsM Ventures RA Capital

Artios Pharmaartios.com in 𝕏

Artios develops DNA Damage Response (DDR)-based therapeutics for hard-to-treat solid tumors, including small-molecule inhibitors targeting ATR (alnodesertib) and DNA polymerase theta (ART6043).

BiotechHealthtech

Co-investorsAndera Partners M Ventures Pfizer Venture Investments RA Capital Sofinnova Partners SV Health Investors

Arvada

AstronauTx

Co-investorsSV Health Investors

Atalantaatalantatx.com in 𝕏Jan 2025 · $97M

Atalanta develops RNA interference-based therapeutics aimed at treating central nervous system and neurological diseases.

BiotechHealthtech

Co-investorsF-Prime Capital RiverVest Venture Partners Sanofi Ventures abrdn plc EQT Life Sciences

Averna Therapeutics

Creates gene therapies that integrate therapeutic genes into patients' genomes to treat genetic disorders.

HealthtechWatertown, US

Thomas Barnes(Chief Executive Officer/President)Richard Morris(Chief Financial Officer)

BoardRoy Amariglio(Director)Nick Olsen(Director)Stephen Squinto(Director)inMichal Silverberg(Director)

Co-investorsDeep Insight OrbiMed

Avernatxavernatx.com in

Averna Therapeutics is a biotechnology company developing therapeutics.

BiotechDeep TechMedical Devices

Thomas M. Barnes(CEO & Board Member)

Co-investorsDeep Insight Delos Capital OrbiMed

CatalYmcatalym.com in

CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a protein it identified as a cancer therapy resistance mechanism, aiming to restore anti-tumor immune activity and improve responses to checkpoint inhibitors.

BiotechHealthtech

Co-investorsBayern Kapital Canaan Partners Jeito Capital BioGeneration Ventures Bioqube Ventures

Citryllcitryll.com in

Citryll is a biotech company developing CIT-013, a first-in-class monoclonal antibody that targets Extracellular Traps (ETs) to treat immune-mediated inflammatory diseases, with a focus on rheumatoid arthritis and hidradenitis suppurativa.

BiotechHealthtechMedical DevicesOss, NL

Co-investorsBOM Curie Capital Pureos Bioventures BioGeneration Ventures Forbion

Epi Biologicsepibiologics.com in

Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.

BiotechMedical DevicesSan Mateo, US

Ann Lee-Karlon(Executive Officer, Director)Mitchell Mutz(Executive Officer, Director)James Wells(Director)

BoardSamuel Bjork(Director)Alexandra Cantley(Director)Seiji Miyahara(Director)

Co-investorsAvego BioScience Capital GV (Google Ventures)Mission Biocapital Roche Venture Fund Samsara BioCapital Taiho Ventures, LLC +3 more

Epsilogenepsilogen.com in

Epsilogen develops antibody therapeutics based on the IgE, IgA, and IgG immunoglobulin isotypes for the treatment of cancer, matching each isotype to specific tumor types and combining isotypes into single antibody molecules.

BiotechHealthtech

Tim Wilson(Chief Executive Officer)Kevin FitzGerald(Chief Scientific Officer)Cristina Oliva(Chief Medical Officer)Nick Robbins-Cherry(Chief Financial Officer)Elizabeth Hardaker(Chief Translational Science Officer)

Co-investors3B Future Health Fund AlbionVC Epidarex Capital Global BioAccess Fund UCL Technology Fund BioGeneration Ventures

Exo Therapeuticsexo-therapeutics.com in 𝕏

Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.

BiotechDeep TechMedical Devices

David Liu, PhD(Founder)Alan Saghatelian, PhD(Co-Founder)David LiuAlan Saghetelian

Co-investorsNewpath Partners CRV (Charles River Ventures)Nextech Invest Raptor Group Samsara BioCapital Casdin Capital

Expansion Therapeutics

BiotechDel Mar, US

Matthew Disney(Director)Paul Stone(Executive Officer)inYujiro Hata(Director)Kevin Forrest(Executive Officer, Director)

BoardScott Rocklage(Executive Officer, Director)inJason Hafler(Director)in

Co-investors5AM Ventures Kleiner Perkins Sanofi Ventures

F2Gf2g.com

F2G is a biotechnology company developing novel antifungal therapies to treat rare, life-threatening fungal infections in defined patient populations.

BiotechHealthtech

Co-investorsAdvent Life Sciences Aisling Capital AMR Action Fund Astellas Venture Management LLC Brace Pharma Sofinnova Partners +3 more

Forefore.bio in 𝕏

Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program.

BiotechHealthtechMedical DevicesPhiladelphia, US

Co-investorsLG Technology Ventures OrbiMed Pontifax Venture Capital Windham Capital Partners Medicxi SymBiosis

Fore Biotherapeutics

Provides functional information about mutations and drug responses to enable precision oncology treatments.

Co-investorsSR One Capital Management Windham Capital Partners

FoRx Therapeuticsforxtherapeutics.com in

FoRx Therapeutics is a clinical-stage biotechnology company developing small-molecule drugs that target DNA replication stress in treatment-resistant cancers.

BiotechDeep TechHealthtechBasel, CH

Co-investorsM Ventures Pfizer Venture Investments

Immunitas Therapeuticsimmunitastx.com inAug 2021

Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies.

BiotechDigital HealthMedical DevicesWaltham, US

Amanda Wagner(Executive Officer)Dan Matloff(Executive Officer)Jiaping Gu(Director)Jeffrey Goldberg(Executive Officer, Director)

BoardLaura Brass(Director)inKai Wucherpfennig(Director)

Co-investorsDC Investment Partners Longwood Fund Medical Excellence Capital Ono Venture Investment, Inc.Solasta Ventures Agent Capital +2 more

Kynexiskynexistx.com in 𝕏

Kynexis is a clinical-stage biotech developing KYN-5356, an oral small-molecule KAT-II inhibitor targeting the kynurenine pathway to improve cognition in neurological diseases.

BiotechDeep TechHealthtech

Robert Schwarcz(Scientific Co-founder)Carol Tamminga(Scientific Co-founder & Chair of the SAB)Christer Köhler(Founding Director)Kees Been(Chief Executive Officer)inJens Wendland(Chief Medical Officer)inNeil Swami(Chief Business Officer)

Co-investorsYsios Capital Forbion Sunstone Capital

LoQus23loqus23.com in

LoQus23 Therapeutics is a drug discovery company developing treatments for triplet repeat expansion diseases such as Huntington's disease, focused on preclinical CNS and neuroscience research.

BiotechDeep TechCambridge, GB

David Reynolds(Co-founder & CEO)inCaroline Benn(Co-founder & CSO)in

Co-investorsSV Health Investors Dementia Discovery Fund Forbion

NRG Therapeuticsnrgtherapeutics.com inSep 2025

NRG Therapeutics is a clinical-stage neuroscience drug discovery company developing disease-modifying, oral small-molecule medicines that target mitochondrial function via inhibition of the mitochondrial permeability transition pore.

BiotechHealthtechLongevity

Co-investorsCriteria Bio Ventures M Ventures SV Health Investors British Business Bank Dementia Discovery Fund

Peptonepeptone.io in

Peptone develops a product engine to design small-molecule drug candidates targeting intrinsically disordered proteins, which have been difficult to address with conventional drug discovery approaches.

AI & Machine LearningBiotechDeep Tech

Co-investorsBessemer Venture Partners Hoxton Ventures Walden Catalyst F-Prime Capital Founders Factory Founders Factory NY

Protegoprotegosolutions.io 𝕏Defunct

Protego provides chargeback management software that automates dispute processes and tracks chargebacks in real time to help merchants identify patterns in fraudulent activity and recover revenue.

CybersecurityEnterprise SoftwareSaaSBogotá, CO

Pablo Rojas(Founder)in

Co-investorsY Combinator Forbion Glilot Capital Partners Omega Funds YK Bioventures

Protegoprotegobio.com

Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones.

AI & Machine LearningBiotechDeep TechDigital HealthSan Diego, US

Co-investorsDroia Ventures Digitalis Ventures Forbion Lightspeed Venture Partners MPM BioImpact Vida Ventures +1 more

Rapptarappta-therapeutics.com

Rappta Therapeutics develops a first-in-class series of anti-cancer molecular glues that reactivate the tumor suppressor enzyme PP2A (protein phosphatase 2A).

BiotechHealthtech

Co-investorsAdvent Life Sciences Novo Holdings

RhyGaze

Co-investorsF-Prime Capital

Ribon Therapeutics in

BiotechLexington, US

Victoria M. Richon(Executive Officer, Director)

BoardCameron Wheeler(Director)Jonathan Root(Director)Laurence Lasky(Director)

Co-investorsAvego BioScience Capital OUP (Osage University Partners)Peregrine Ventures AbbVie The Column Group

Salvinasip-baselarea.com in 𝕏

SIP Basel Area provides move-in ready wetlabs and serviced offices with flexible contracts, ranging from single benches and hot desks to turnkey labs and headquarters.

BiotechPropTech

Sidewinder Therapeutics

Advancing precision bispecific antibody-drug conjugates to treat cancer

Co-investorsDCVC (Data Collective)DCVC Bio Frazier Life Sciences

Sidewinderbiosidewinderbio.com in

Sidewinder Therapeutics is a biotechnology company focused on oncology drug discovery and development, working on next-generation cancer treatments.

BiotechHealthtechMedical DevicesSan Diego, US

Eric Murphy(Chief Executive Officer, Co-Founder, & Director)

Co-investorsAstellas Venture Management LLC Frazier Life Sciences Longwood Fund OrbiMed Insight Partners

Tagworks Pharmaceuticalstagworkspharma.com in 𝕏Jun 2023

Tagworks Pharmaceuticals develops cancer therapies using its Click-to-Release platform, a chemical reaction that activates antibody-drug conjugates (ADCs), masked immunomodulators, and other prodrugs on-target while deactivating radioimmunotherapies off-target.

BiotechHealthtechMedical DevicesNijmegen, NL

Co-investorsBif Lightstone Ventures New Enterprise Associates (NEA)Ysios Capital Gilde Healthcare Oost NL

Tephatepha.comMar 2012

HealthtechLexington, US

Simon Williams(Executive Officer, Director)John Hartnett(Executive Officer)

BoardRichard B. Emmitt(Director)Edward M. Giles(Director)Anthony J. Sinskey(Director)

Co-investorsThe Vertical Group

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 2

IPOs and acquisitions across the tracked portfolio

Adicet BioNASDAQ: ACETAileron TherapeuticsNASDAQ: RNTX

Portfolio news

latest coverage across their companies

Finance Watch: Venture Capital Investors Meet Biotechs In The Middle

Kynexis · insights.citeline.com · Aug 20, 2026

Etched's $21b valuation, Smack's battlefield software, and Goldman's real estate buy

Alesta · axios.com · Aug 18, 2026

InduPro raises $77M, begins first human trial of cancer drug – GeekWire

Ribon Therapeutics · geekwire.com · Aug 14, 2026

RA Capital reports 9.99% stake in Adicet Bio | ACET SEC Filing - Form SCHEDULE 13G/A

Adicet Bio · stocktitan.net · Aug 14, 2026

Fore Biotherapeutics lands $67M extension to support ongoing cancer drug development

Fore · technical.ly · Aug 6, 2026

Aravax Awarded FDA Fast Track Designation for PVX108, a Next-Generation Immunotherapy for the Treatment of Peanut Allergy - BioSpace

Aravax · biospace.com · Aug 3, 2026

Inforcer raises $50M to help prepare smaller businesses for a new world of AI and security risks

Sidewinderbio · techcrunch.com · Jul 30, 2026

Rilian Raises $17.5M in Seed Funding

Protego · finsmes.com · Apr 23, 2026

Frequently asked questions

How many investments has Novartis Venture Fund made?: Novartis Venture Fund has 30 tracked investments, including 4 dated in the last 24 months.
What stage does Novartis Venture Fund invest at?: Novartis Venture Fund invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What is Novartis Venture Fund's typical check size?: Novartis Venture Fund typically writes checks of $5M – $25M.
What sectors does Novartis Venture Fund focus on?: Novartis Venture Fund focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is Novartis Venture Fund located?: Novartis Venture Fund is headquartered in Basel, CH.
Does Novartis Venture Fund lead rounds?: Yes, Novartis Venture Fund leads investment rounds.
Who does Novartis Venture Fund co-invest with?: Novartis Venture Fund most often shares deals with Pfizer Venture Investments, OrbiMed, SV Health Investors, among 63 tracked co-investors.

Co-investors · 27

Forbion

Forbion is a global venture capital firm focused on advancing biotech innovations and sustainable solutions aimed at improving human and planetary health.

Both backed · 7

Amphista Citryll F2G Granite Bio Kynexis LoQus23 Protego

Pfizer Venture Investments

Pfizer Venture Investments is a strategic venture fund that doesn't require product or technology rights as a condition of investing, giving founders independence while still aiming for future collaboration with Pfizer, and its team blends venture investing with business development and drug discovery expertise to back frontier scientific bets—such as neuroscience, in-vivo cell engineering, dark-genome target discovery, and the blockchain-based longevity accelerator VitaDAO—that many biotech investors avoid. The fund also runs an active China strategy through a locally based venture vehicle and direct investments like OTR Therapeutics, and it has become a channel for strategic deals, with portfolio companies acquired by AbbVie, Ipsen, and Gilead/Kite.

Both backed · 5

Anaveon Artios Pharma FoRx Therapeutics Mediar Therapeutics Vivet Therapeutics

$5M – $20M

RA Capital

RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.

Both backed · 4

Artios Pharma GentiBio HYKU BiosciencesArtios

BioGeneration Ventures

BioGeneration Ventures is a venture capital firm that invests in early-stage biotech companies in Europe, with a focus on healthcare innovations.

Both backed · 4

CatalYm Citryll Epsilogen RhyGaze AG

Sanofi Ventures

Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.

Both backed · 4

Atalanta Expansion Therapeutics Granite Bio Splice Bio

$5M

Ysios Capital

Ysios Capital is a life sciences investor that finances innovative biotech companies worldwide, providing resources to develop novel therapies for indications with high unmet medical needs.

Both backed · 4

Kynexis Splice Bio Tagworks Pharmaceuticals Vivet Therapeutics

$5.4M – $21.6M

Sofinnova Partners

Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.

Both backed · 3

Artios Pharma F2G Mediar Therapeutics

$540K – $27M

Advent Life Sciences

Advent Life Sciences is a trans-Atlantic venture capital firm investing in early and mid-stage life sciences companies across the UK, Europe and the USA.

Both backed · 3

Amphista F2G Rappta

Roche Venture Fund

Roche Venture Fund is a corporate venture arm that invests in early-stage biotech and diagnostics companies across more than 10 countries, with a portfolio exceeding 30 portfolio companies. The fund is headquartered in Basel, Switzerland.

Both backed · 3

Epi Biologics Splice Bio Vivet Therapeutics

$648K – $3.2M

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.

Both backed · 2

Epi Biologics RhyGaze AG

$250K – $50M

New Enterprise Associates (NEA)

New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.

Both backed · 2

Splice Bio Tagworks Pharmaceuticals

$200K – $40M

EQT Life Sciences

EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.

Both backed · 2

Atalanta Splice Bio

$11M – $66M

▶15 more co-investors

MPM BioImpact DCVC (Data Collective)SR One Capital Management Frazier Healthcare Partners Andera Partners Omega Funds Lightstone Ventures 3B Future Health Fund Bayern Kapital Atlas Venture Deerfield Management Company Sofinnova Ventures Seventure Partners Inkef Clarus Ventures

Firms observed investing alongside Novartis Venture Fund, from public investor directories. Shared companies are the overlap with Novartis Venture Fund's recorded portfolio.

Similar investors

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M

Khosla Ventures

Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.

$5K – $50M

Pontifax Venture Capital

Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.

$6.3M – $128M

Accelmed Partners

Accelmed Partners is a healthcare technology investment firm that applies a private equity approach to a sector traditionally served by venture and early-stage growth investors, focusing on tools & diagnostics, digital health, and tech-enabled services.